Notice: 函数 WP_Styles::add 的调用方法不正确。 The style with the handle "storefront-woocommerce-style" was enqueued with dependencies that are not registered: storefront-style. 请查阅调试 WordPress来获取更多信息。 (这个消息是在 6.9.1 版本添加的。) in /wordpress/wp-includes/functions.php on line 6260

KB-1169

Ramucirumab

Home » Ramucirumab

Background of Ramucirumab

Ramucirumab is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2, a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D. Through blocking activation of VEGFR-2 by VEGF-A and the other VEGF ligands, ramucirumab inhibits the angiogenesis pathways involved in the development and progression of gastric cancer.

Specifications

Catalog Number:
KB-1169
Antibody Name:
Ramucirumab
Isotype:
Human IgG1, kappa
FC Muations:
Wild Type
Target:
VEGFR2
Species Reactivity:
Human
Host Cell Line:
EXPI CHO
Purification Method:
Affinity purified
Concentration:
>2 mg/mL
Formulation:
50 mM sodium citrate,150mM NaCl,pH5.5
Purity:
>95% by SDS-PAGE and SEC-HPLC
Validation:
FACS
Endotoxin Level:
<0.2 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Storage:
It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability:
Stable for twelve months from date of receipt when stored at -20°C to -80°C;Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

  1. Cyramza (ramucirumab) package insert. Eli Lilly and Company. 2014 Retrieved from http://www.cyramza.com.
  2. Wadhwa Roopma, Taketa Takashi, Sudo Kazuki, Blum-Murphy Mariela, Ajani Jaffer A. Ramucirumab: a novel antiangiogenic agent. Future Oncology (London, England) 2013;9:789–795.